Howard Marks’s BeOne Medicines Ltd ONC Stock Holding History

Howard Marks’s Portfolio ONC Stock Details ONC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-26,700	Closed	-$3.31M	–	207
2019 Q2	$3.31M	Buy	+26,700	New	+$3.39M	0.06%	140

Other funds holding ONC

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

CII

Capital International Inc Los Angeles, California $14.3B AUM 34.19% 1-Year Est. Return

Howard Marks's ONC Position: Q3 2019 in Review

Howard Marks sold out of BeOne Medicines Ltd (ONC) in Q3 2019, closing a stake of 26,700 shares — an estimated $3.31M sold.

Howard Marks first reported a position in ONC in Q2 2019 and held it in 1 quarter. The position peaked at $3.31M in Q2 2019. 196 funds tracked by Wall St. Rank hold ONC as of Q3 2019.

Howard Marks reported no remaining BeOne Medicines Ltd position as of Q3 2019 after selling out during the quarter.
Howard Marks sold 26,700 BeOne Medicines Ltd shares in Q3 2019, an estimated $3.31M.
Howard Marks first reported a position in BeOne Medicines Ltd in Q2 2019 and held it in 1 quarter.
Howard Marks's BeOne Medicines Ltd position peaked at $3.31M in Q2 2019.
196 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q3 2019.

Based on Oaktree Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.